27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Gain Therapeutics Inc (NASDAQ:GANX) has presented new preclinical data from its Parkinson's Disease (PD) program at the 2022 Synuclein Meeting.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
- The data show that the lead compound GT-02287 increases the levels and activity of the beta-glucocerebrosidase (GCase) protein, improves lysosomal health, and corrects abnormal phenotypes of PD.
- The data also showed improved neuronal network connections and neuron survival.
- Related: Gain Therapeutics Posts Encouraging Preclinical Data From Parkinson's, Alzheimer's Programs.
- The data were generated in two different in vitro models covering both WT and the two most pathogenic GBA1 mutations, L444P and N370S.
- Price Action: GANX shares surged 43.2% at $6.00 during the market session on the last check Tuesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.